Details
The document's own metadata, straight from the source system.
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jul 22, 2026Comment from Concordare Trials, Inc.SupportBusiness📎 Attachment
Concordare Trials, Inc., a clinical trial technology company, supports the Expedited IND Pilot Program and advocates for the use of structured, machine-readable protocol data to achieve the program's parallelization goals. They recommend specific technical criteria for Qualified Research Institutions (QRIs), including standards alignment with ICH M11 and CDISC USDM, and offer to share operational data and participate in technical discussions.
Read comment → - Jul 22, 2026Comment from Jordan DespanieSupportIndividual📎 Attachment
Dr. Jordan Despanie supports the establishment of the Expedited Investigational New Drug (IND) Acceleration Pilot Program to accelerate First-in-Human timelines and maintain U.S. biopharmaceutical competitiveness. The commenter proposes a five-pillar regulatory architecture involving Bayesian clinical trial design, AI-driven preclinical de-risking, an "Architecture of Trust" for AI governance, site-specific infrastructure, and alignment with late-stage incentives.
Read comment → - Jul 20, 2026Comment from Optisources IncSupportBusiness📎 Attachment
Optisources, Inc., a small business technology consulting firm, supports the Expedited IND Pilot Program but recommends specific technical requirements to ensure data integrity and equity. They advocate for a platform featuring tamper-evident provenance, a governed semantic layer for heterogeneous data ingestion, AI-assisted classification, and a common submission platform to lower barriers for smaller organizations.
Read comment → - Jul 16, 2026Comment from Veeva SystemsSupportBusiness📎 Attachment
Veeva Systems, a life sciences software provider, supports the proposed Expedited IND Pilot Program and urges the FDA to include technology partners in the initiative. They argue that a single, streamlined technology platform is essential for standardizing data, ensuring auditability, and enabling cross-QRI comparison.
Read comment → - Jul 8, 2026Comment from Progress Federal SolutionsSupportBusiness📎 Attachment
Progress Federal Solutions supports the Expedited Investigational New Drug (IND) pilot program and emphasizes that the success of the initiative depends on a robust data architecture. They recommend that the FDA prioritize a platform capable of unified retrieval, semantic alignment via ontology, governed decision logic, data-layer security, and auditable defensibility to ensure actual timeline savings.
Read comment →